Funding for this research was provided by:
Seventh Framework Programme (305823)
National Institute for Health Research University College London Hospitals Biomedical Research Centre (BRC326/III/RS/101350)
Text and Data Mining valid from 2019-04-30
Received: 15 July 2018
Accepted: 1 April 2019
First Online: 30 April 2019
Ethics approval and consent to participate
: Approval for the study was obtained from London Stanmore Research Ethics Committee (13/LD/1254). All participants gave written informed consent which was reaffirmed immediately prior to the interview.
: All participant quotes are anonymised using a number allocated soley for the purposes of this study. Participants were informed about the inclusion of anonymised quotes in publications as part of the consent process.
: ALD is a shareholder in Magnus Growth, a company that is aiming to take to market a new treatment for placental insufficiency. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.